SUIT-005: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
|abbr=FNS(Oct,PM) | |abbr=FNS(Oct,PM) | ||
|description=[[File:1OctM;2D;3P;4S;5U;6Rot-.png|300px]] | |description=[[File:1OctM;2D;3P;4S;5U;6Rot-.png|300px]] | ||
|info='''A:''' '''short RP2''' [[File:PDF.jpg|100px|link=http://wiki.oroboros.at/images/6/64/SUIT-005.pdf|Bioblast pdf]] ยป[http://wiki.oroboros.at/index.php/File:SUIT-005.pdf Versions] | |info='''A:''' '''short RP2''' when [[Malate anaplerotic pathway control state |malate-anaplerotic activity]] is zero [[File:PDF.jpg|100px|link=http://wiki.oroboros.at/images/6/64/SUIT-005.pdf|Bioblast pdf]] ยป[http://wiki.oroboros.at/index.php/File:SUIT-005.pdf Versions] | ||
}} | }} | ||
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ||
::: '''[[SUIT protocol pattern]]:''' orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama | ::: '''[[SUIT protocol pattern]]:''' orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama | ||
__TOC__ | __TOC__ | ||
ย Communicated by [[Iglesias-Gonzalez J]] | ย Communicated by [[Iglesias-Gonzalez J]], [[Gnaiger E]] (last update 2019-01-26) | ||
== DLP applications == | == DLP applications == | ||
Line 16: | Line 16: | ||
== References == | == References == | ||
{{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT- | {{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT-005]] | ||
|?Was published in year=Year | |?Was published in year=Year | ||
|?Has title=Reference | |?Has title=Reference | ||
Line 31: | Line 31: | ||
== Strengths and limitations == | == Strengths and limitations == | ||
:::+ The protocol provides information on | :::* :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added. | ||
:::+ FNS | ย | ||
:::+ The protocol provides information on F-OXPHOS capacity in the absence of a significant OXPHOS-capacity in the [[malate anaplerotic pathway control state]]. | |||
:::+ | :::+ FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity. | ||
:::+ PM & S reconsitutes TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate. | |||
:::+ Application of the [[cytochrome c]] test early in the protocol ensures comparability of all states in case of any effect of c. | :::+ Application of the [[cytochrome c]] test early in the protocol ensures comparability of all states in case of any effect of c. | ||
ย | |||
:::- F OXPHOS capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) | :::- F-OXPHOS capacity may be underestimated with Oct. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) & malate increased OXPHOS-capacity by 26% (Lemuieux et al 2011). | ||
:::- SRot | :::- SRot<sub>''E''</sub> may be underestimated if S is not saturating. | ||
ย | |||
== Compare SUIT protocols == | == Compare SUIT protocols == | ||
::::* [[SUIT-002]] | ::::* [[SUIT-002]] check for malate-linked anaplerotic activity | ||
{{MitoPedia concepts | {{MitoPedia concepts |
Revision as of 15:22, 26 January 2019
Description
Abbreviation: FNS(Oct,PM)
Reference: A: short RP2 when malate-anaplerotic activity is zero ยปVersions
- SUIT-category: FNS(Oct,PM)
- SUIT protocol pattern: orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama
Communicated by Iglesias-Gonzalez J, Gnaiger E (last update 2019-01-26)
DLP applications
- SUIT-005 O2 pfi D011 for permeabilized fibers
References
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML(n) | F(N) | FAO | 1OctM
|
2D | OctMP | F(N) | FAO | 1OCtM;2D
|
2c | OctMcP | F(N) | FAO | 1OCtM;2D;2c
|
3P | OctPMP | FN | F&CI | 1OctM;2D;2c;3P
|
4S | OctPMSP | FNS | F&CI&II | 1OctM;2D;2c;3P;4S
|
5U | OctPMSE | FNS | F&CI&II | 1OctM;2D;2c;3P;4S;5U
|
6Rot | SE | S | CII | 1OctM;2D;3P;4S;5U;6Rot
|
7Ama | ROX | 1OctM;2D;3P;4S;5U;6Rot;7Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- ยป Electron transfer pathway
- ยป Fatty acid oxidation pathway control state, F
- ยป NADH electron transfer-pathway state, N
- ยป Succinate pathway control state, S
- ยป NS-pathway control state, NS
- ยป Glycerophosphate pathway control state, Gp
- ยป Complex IV single step, CIV
- ยป Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- ยป Glutamate, G
- ยป Glycerophosphate, Gp
- ยป Malate, M
- ยป Octanoylcarnitine, Oct
- ยป Pyruvate, P
- ยป Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
- + The protocol provides information on F-OXPHOS capacity in the absence of a significant OXPHOS-capacity in the malate anaplerotic pathway control state.
- + FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity.
- + PM & S reconsitutes TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate.
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- - F-OXPHOS capacity may be underestimated with Oct. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) & malate increased OXPHOS-capacity by 26% (Lemuieux et al 2011).
- - SRotE may be underestimated if S is not saturating.
Compare SUIT protocols
- SUIT-002 check for malate-linked anaplerotic activity
MitoPedia concepts:
MiP concept,
SUIT protocol,
Recommended
MitoPedia methods:
Respirometry